Shire (SHP)

 

Latest News

Shire confirms CFO appointment

Shire said Thomas Dittrich would assume his role as chief financial officer, and become an executive director, on March 1...

Broker Forecast - Liberum Capital issues a broker note on Shire PLC

Liberum Capital today reaffirms its hold investment rating on Shire PLC (LON:SHP) and cut its price target to 4000p (fro...

Broker Forecast - Exane BNP Paribas issues a broker note on Shire PLC

Exane BNP Paribas today reaffirms its outperform investment rating on Shire PLC (LON:SHP) and set its price target at 4...

Broker Forecast - Deutsche Bank issues a broker note on Shire PLC

Deutsche Bank today reaffirms its buy investment rating on Shire PLC (LON:SHP) and set its price target at 5000p.

All News

DateHeadlineSource
19-01-18Shire confirms CFO appointmentStockMarketWire
18-01-18Broker Forecast - Liberum Capital issues a broker note on Shire PLCStockMarketWire
16-01-18Broker Forecast - Exane BNP Paribas issues a broker note on Shire PLCStockMarketWire
11-01-18Broker Forecast - Deutsche Bank issues a broker note on Shire PLCStockMarketWire
08-01-18Housebuilders help drag FTSE lowerStockMarketWire
08-01-18Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare ConferenceRNS
04-01-18Shire to present at the 36th Annual J.P. Morgan Healthcare ConferenceRNS
02-01-18Shire plc : Total voting rightsRNS
02-01-18Shire plc : Director DeclarationRNS
27-12-17Shire seeks FDA approval for new US plasma manufacturing facilityStockMarketWire
27-12-17Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchiseRNS
20-12-17Director Deals - Shire PLC (SHP)StockMarketWire
20-12-17Director Deals - Shire PLC (SHP)StockMarketWire
20-12-17Director Deals - Shire PLC (SHP)StockMarketWire
20-12-17Director Deals - Shire PLC (SHP)StockMarketWire
20-12-17Shire plc : Director/PDMR ShareholdingRNS
20-12-17Broker Forecast - Liberum Capital issues a broker note on Shire PLCStockMarketWire
19-12-17Shire plc : Director DeclarationRNS
13-12-17Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)RNS
08-12-17Shire plc : Directorate changeRNS
05-12-17Shire and Rani enter into collaboration agreementStockMarketWire
05-12-17Shire and Rani Therapeutics Enter into Collaboration to Evaluate Use of the Rani Pill(TM) Technology for the Oral Delivery of Factor TherapyRNS
01-12-17Shire plc : Total voting rightsRNS
01-12-17Shire appoints new R&D headStockMarketWire
01-12-17Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific OfficerRNS
30-11-17U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric PatientsRNS
29-11-17Broker Forecast - Societe Generale issues a broker note on Shire PLCStockMarketWire
24-11-17Shire plc : Block listing Interim ReviewRNS
21-11-17Broker Forecast - HSBC issues a broker note on Shire PLCStockMarketWire
20-11-17FTSE steady at the closeStockMarketWire
20-11-17Shire names new CFOStockMarketWire
20-11-17Shire plc : Directorate changeRNS
14-11-17Broker Forecast - Liberum Capital issues a broker note on Shire PLCStockMarketWire
13-11-17CHMP recommends EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia ARNS
10-11-17Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and OncologyRNS
06-11-17Broker Forecast - Berenberg issues a broker note on Shire PLCStockMarketWire
03-11-17Shire plc : Director/PDMR ShareholdingRNS
01-11-17Shire plc : Director/PDMR ShareholdingRNS
01-11-17Shire plc : Total voting rightsRNS
31-10-17Broker Forecast - HSBC issues a broker note on Shire PLCStockMarketWire

RSS feeds

  • Editorial news feed for LSE:SHP Editorial
  • Regulatory news feed for LSE:SHP Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account